216.98
price down icon0.54%   -1.17
after-market  Dopo l'orario di chiusura:  216.98 
loading
Precedente Chiudi:
$218.15
Aprire:
$219.63
Volume 24 ore:
649.40K
Capitalizzazione di mercato:
$31.88B
Reddito:
$4.58B
Utile/perdita netta:
$958.38M
Rapporto P/E:
35.22
EPS:
6.16
Flusso di cassa netto:
$1.07B
1 W Prestazione:
-0.50%
1M Prestazione:
+16.63%
6M Prestazione:
+41.99%
1 anno Prestazione:
-8.37%
Intervallo 1D:
Value
$216.72
$221.40
Portata 52W:
Value
$132.24
$237.26

Resmed Inc. Stock (RMD) Company Profile

Name
Nome
Resmed Inc.
Name
Telefono
858-836-5000
Name
Indirizzo
9001 Spectrum Center Boulevard, San Diego, CA
Name
Dipendente
6,000
Name
Cinguettio
@resmed
Name
Prossima data di guadagno
2024-04-25
Name
Ultimi documenti SEC
Name
RMD's Discussions on Twitter

Resmed Inc. Stock (RMD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-02-06 Ripresa KeyBanc Capital Markets Overweight
2023-10-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2023-10-12 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-10-09 Aggiornamento JP Morgan Neutral → Overweight
2023-09-29 Downgrade Wolfe Research Outperform → Peer Perform
2023-09-06 Aggiornamento Needham Hold → Buy
2023-09-05 Downgrade UBS Buy → Neutral
2023-08-01 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-05-23 Iniziato UBS Buy
2023-04-14 Iniziato Mizuho Buy
2023-01-17 Aggiornamento JP Morgan Neutral → Overweight
2022-10-28 Downgrade Citigroup Buy → Neutral
2022-10-20 Aggiornamento BofA Securities Neutral → Buy
2022-10-12 Iniziato Jefferies Hold
2022-09-08 Aggiornamento Citigroup Neutral → Buy
2022-08-15 Downgrade CLSA Buy → Outperform
2022-08-12 Downgrade Citigroup Buy → Neutral
2022-08-12 Downgrade JP Morgan Overweight → Neutral
2022-08-12 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-06-06 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2022-04-06 Iniziato Wolfe Research Outperform
2022-01-31 Aggiornamento Citigroup Neutral → Buy
2022-01-31 Aggiornamento Goldman Neutral → Buy
2022-01-28 Aggiornamento RBC Capital Mkts Underperform → Sector Perform
2022-01-24 Aggiornamento BofA Securities Underperform → Neutral
2022-01-24 Aggiornamento JP Morgan Neutral → Overweight
2022-01-13 Aggiornamento CLSA Outperform → Buy
2022-01-13 Aggiornamento Robert W. Baird Neutral → Outperform
2021-12-21 Aggiornamento KeyBanc Capital Markets Sector Weight → Overweight
2021-12-06 Aggiornamento Macquarie Neutral → Outperform
2021-10-22 Aggiornamento CLSA Underperform → Outperform
2021-08-02 Downgrade CLSA Outperform → Sell
2021-08-02 Downgrade Needham Buy → Hold
2021-07-28 Aggiornamento Jefferies Underperform → Hold
2021-07-26 Downgrade JP Morgan Overweight → Neutral
2021-07-14 Iniziato RBC Capital Mkts Underperform
2021-06-28 Downgrade Citigroup Buy → Neutral
2021-06-22 Aggiornamento Macquarie Neutral → Outperform
2021-06-22 Iniziato Robert W. Baird Neutral
2021-06-21 Reiterato Needham Buy
2021-06-16 Downgrade BofA Securities Neutral → Underperform
2021-06-09 Aggiornamento CLSA Sell → Outperform
2021-05-21 Aggiornamento JP Morgan Neutral → Overweight
2021-05-11 Aggiornamento Citigroup Neutral → Buy
2021-04-30 Downgrade Citigroup Buy → Neutral
2021-03-16 Aggiornamento Needham Hold → Buy
2020-11-02 Aggiornamento UBS Neutral → Buy
2020-10-30 Aggiornamento JP Morgan Underweight → Neutral
2020-10-27 Aggiornamento BofA Securities Underperform → Neutral
2020-08-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-06-17 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-05-01 Downgrade JP Morgan Neutral → Underweight
2020-05-01 Aggiornamento Oppenheimer Perform → Outperform
2020-02-18 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-02-03 Iniziato CLSA Underperform
2020-01-31 Downgrade UBS Buy → Neutral
2020-01-10 Iniziato Oppenheimer Perform
2019-11-22 Iniziato KeyBanc Capital Markets Sector Weight
2019-07-29 Aggiornamento UBS Neutral → Buy
2019-07-16 Downgrade UBS Buy → Neutral
2019-05-06 Aggiornamento UBS Neutral → Buy
2019-04-18 Aggiornamento JP Morgan Underweight → Neutral
2019-01-25 Downgrade Goldman Buy → Neutral
2019-01-25 Downgrade JP Morgan Neutral → Underweight
2018-10-26 Aggiornamento Credit Suisse Neutral → Outperform
2018-07-02 Iniziato Goldman Buy
Mostra tutto

Resmed Inc. Azioni (RMD) Dati Finanziari

Resmed Inc. (RMD) Reddito 2024

RMD ha riportato un ricavo (TTM) di $4.58 miliardi per il trimestre terminato il 2024-03-31, un +14.16% salita anno su anno.
loading

Resmed Inc. (RMD) Reddito netto 2024

RMD l'utile netto (TTM) è stato di $958.38 milioni per il trimestre terminato il 2024-03-31, un +11.06% aumento anno su anno.
loading

Resmed Inc. (RMD) Flusso di cassa 2024

RMD ha registrato un flusso di cassa disponibile (TTM) di $1.07 miliardi per il trimestre conclusosi con 2024-03-31, un +162.78% aumento anno su anno.
loading

Resmed Inc. (RMD) Utile per azione 2024

L'utile per azione (TTM) di RMD è stato pari a $6.51 per il trimestre terminato il 2024-03-31, un +10.90% crescita anno su anno.
loading
medical_instruments_supplies WST
$365.02
price down icon 0.93%
medical_instruments_supplies ALC
$79.57
price up icon 1.47%
medical_instruments_supplies BAX
$36.89
price down icon 0.05%
medical_instruments_supplies COO
$90.64
price up icon 0.99%
$76.54
price up icon 0.83%
Capitalizzazione:     |  Volume (24 ore):